JP2020520510A - 個体およびコホートの薬理学的表現型予測プラットフォーム - Google Patents
個体およびコホートの薬理学的表現型予測プラットフォーム Download PDFInfo
- Publication number
- JP2020520510A JP2020520510A JP2019562325A JP2019562325A JP2020520510A JP 2020520510 A JP2020520510 A JP 2020520510A JP 2019562325 A JP2019562325 A JP 2019562325A JP 2019562325 A JP2019562325 A JP 2019562325A JP 2020520510 A JP2020520510 A JP 2020520510A
- Authority
- JP
- Japan
- Prior art keywords
- data
- patient
- pharmacological
- gene
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000144 pharmacologic effect Effects 0.000 title claims abstract description 369
- 229940079593 drug Drugs 0.000 claims abstract description 223
- 239000003814 drug Substances 0.000 claims abstract description 223
- 230000007613 environmental effect Effects 0.000 claims abstract description 187
- 230000004044 response Effects 0.000 claims abstract description 174
- 238000012549 training Methods 0.000 claims abstract description 114
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 112
- 238000013179 statistical model Methods 0.000 claims abstract description 106
- 201000010099 disease Diseases 0.000 claims abstract description 96
- 201000009032 substance abuse Diseases 0.000 claims abstract description 87
- 238000010801 machine learning Methods 0.000 claims abstract description 65
- 231100000736 substance abuse Toxicity 0.000 claims abstract description 51
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims abstract description 25
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 21
- 230000002411 adverse Effects 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 169
- 238000000034 method Methods 0.000 claims description 139
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims description 63
- 229960005080 warfarin Drugs 0.000 claims description 63
- 230000035882 stress Effects 0.000 claims description 46
- 230000015654 memory Effects 0.000 claims description 36
- 230000037361 pathway Effects 0.000 claims description 35
- 230000036541 health Effects 0.000 claims description 32
- 238000004458 analytical method Methods 0.000 claims description 31
- 238000012502 risk assessment Methods 0.000 claims description 29
- 239000012472 biological sample Substances 0.000 claims description 24
- 238000004891 communication Methods 0.000 claims description 18
- 208000035475 disorder Diseases 0.000 claims description 16
- 238000003766 bioinformatics method Methods 0.000 claims description 12
- 238000002705 metabolomic analysis Methods 0.000 claims description 12
- 230000001431 metabolomic effect Effects 0.000 claims description 12
- 208000017667 Chronic Disease Diseases 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 108700026220 vif Genes Proteins 0.000 claims description 9
- 108700028369 Alleles Proteins 0.000 claims description 8
- 102100031752 Fibrinogen alpha chain Human genes 0.000 claims description 7
- 101710137044 Fibrinogen alpha chain Proteins 0.000 claims description 7
- 102100035047 Flavin-containing monooxygenase 5 Human genes 0.000 claims description 7
- 102100027619 Histidine-rich glycoprotein Human genes 0.000 claims description 7
- 101000613347 Homo sapiens Polycomb group RING finger protein 3 Proteins 0.000 claims description 7
- 101000630717 Homo sapiens Surfeit locus protein 4 Proteins 0.000 claims description 7
- 102100035792 Kininogen-1 Human genes 0.000 claims description 7
- 101710111227 Kininogen-1 Proteins 0.000 claims description 7
- 102100040920 Polycomb group RING finger protein 3 Human genes 0.000 claims description 7
- 102100029500 Prostasin Human genes 0.000 claims description 7
- 102100026355 Surfeit locus protein 4 Human genes 0.000 claims description 7
- 108010057167 dimethylaniline monooxygenase (N-oxide forming) Proteins 0.000 claims description 7
- 108010044853 histidine-rich proteins Proteins 0.000 claims description 7
- 230000009711 regulatory function Effects 0.000 claims description 7
- 230000000472 traumatic effect Effects 0.000 claims description 7
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 claims description 6
- 101000878134 Homo sapiens Complement factor H-related protein 5 Proteins 0.000 claims description 6
- 101001125574 Homo sapiens Prostasin Proteins 0.000 claims description 6
- 102100039024 Sphingosine kinase 1 Human genes 0.000 claims description 6
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 230000015271 coagulation Effects 0.000 claims description 6
- 238000005345 coagulation Methods 0.000 claims description 6
- 206010067484 Adverse reaction Diseases 0.000 claims description 5
- 108010014251 Muramidase Proteins 0.000 claims description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 5
- 108700011958 Ubiquitin-Specific Peptidase 7 Proteins 0.000 claims description 5
- 229960000274 lysozyme Drugs 0.000 claims description 5
- 239000004325 lysozyme Substances 0.000 claims description 5
- 235000010335 lysozyme Nutrition 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims description 4
- 102100035954 Choline transporter-like protein 2 Human genes 0.000 claims description 4
- 101000799180 Homo sapiens Short transient receptor potential channel 4-associated protein Proteins 0.000 claims description 4
- 108091007001 SLC44A2 Proteins 0.000 claims description 4
- 102100034106 Short transient receptor potential channel 4-associated protein Human genes 0.000 claims description 4
- 101150020913 USP7 gene Proteins 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 101000846124 Homo sapiens Short transient receptor potential channel 4 Proteins 0.000 claims description 3
- 102100031771 Short transient receptor potential channel 4 Human genes 0.000 claims description 3
- 230000000740 bleeding effect Effects 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 3
- 108010031970 prostasin Proteins 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000037326 chronic stress Effects 0.000 claims description 2
- 102000016943 Muramidase Human genes 0.000 claims 4
- 108010035597 sphingosine kinase Proteins 0.000 claims 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 102000052151 Ubiquitin-Specific Peptidase 7 Human genes 0.000 claims 2
- 108010066496 Ubiquitin-Specific Proteases Proteins 0.000 claims 2
- 102000018390 Ubiquitin-Specific Proteases Human genes 0.000 claims 2
- 229940126752 Ubiquitin-specific protease 7 inhibitor Drugs 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 abstract description 21
- 238000011160 research Methods 0.000 abstract description 17
- 230000008406 drug-drug interaction Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 230000005180 public health Effects 0.000 abstract description 2
- 238000005457 optimization Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 description 137
- 238000012360 testing method Methods 0.000 description 61
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 41
- 229910052744 lithium Inorganic materials 0.000 description 41
- 208000014674 injury Diseases 0.000 description 40
- 230000008733 trauma Effects 0.000 description 40
- 210000004185 liver Anatomy 0.000 description 39
- 238000004422 calculation algorithm Methods 0.000 description 29
- 230000000875 corresponding effect Effects 0.000 description 29
- 238000011156 evaluation Methods 0.000 description 22
- 108010077544 Chromatin Proteins 0.000 description 18
- 210000003483 chromatin Anatomy 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 238000003066 decision tree Methods 0.000 description 14
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 14
- 210000000813 small intestine Anatomy 0.000 description 14
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 12
- 230000035479 physiological effects, processes and functions Effects 0.000 description 12
- 230000002792 vascular Effects 0.000 description 12
- 238000013528 artificial neural network Methods 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000002207 metabolite Substances 0.000 description 11
- 238000012706 support-vector machine Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 208000020925 Bipolar disease Diseases 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 238000013507 mapping Methods 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000012098 association analyses Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 229940127219 anticoagulant drug Drugs 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 229940000406 drug candidate Drugs 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002547 new drug Substances 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002974 pharmacogenomic effect Effects 0.000 description 6
- 238000000528 statistical test Methods 0.000 description 6
- 210000004243 sweat Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 229960000604 valproic acid Drugs 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 206010061623 Adverse drug reaction Diseases 0.000 description 5
- 208000028017 Psychotic disease Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000013135 deep learning Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000003196 psychodysleptic agent Substances 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 102000009839 Endothelial Protein C Receptor Human genes 0.000 description 4
- 108010009900 Endothelial Protein C Receptor Proteins 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 101100029173 Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) SNP2 gene Proteins 0.000 description 4
- 101100094821 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SMX2 gene Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 230000004931 aggregating effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000002060 circadian Effects 0.000 description 4
- 230000027288 circadian rhythm Effects 0.000 description 4
- 238000013500 data storage Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 230000002996 emotional effect Effects 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 235000019645 odor Nutrition 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 108010047303 von Willebrand Factor Proteins 0.000 description 4
- 102100036537 von Willebrand factor Human genes 0.000 description 4
- 229960001134 von willebrand factor Drugs 0.000 description 4
- 102000004602 Aldo-Keto Reductase Family 1 Member C3 Human genes 0.000 description 3
- 102100022463 Alpha-1-acid glycoprotein 1 Human genes 0.000 description 3
- 101710186701 Alpha-1-acid glycoprotein 1 Proteins 0.000 description 3
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 3
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 3
- 102100024902 Cytochrome P450 4F2 Human genes 0.000 description 3
- 206010014522 Embolism venous Diseases 0.000 description 3
- 102100024783 Fibrinogen gamma chain Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000919361 Homo sapiens Cytochrome P450 2C19 Proteins 0.000 description 3
- 101000919359 Homo sapiens Cytochrome P450 2C9 Proteins 0.000 description 3
- 101000909122 Homo sapiens Cytochrome P450 4F2 Proteins 0.000 description 3
- 102100033468 Lysozyme C Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010065942 Prostaglandin-F synthase Proteins 0.000 description 3
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 3
- 102100031070 Serine protease 53 Human genes 0.000 description 3
- 102100027975 Syntaxin-4 Human genes 0.000 description 3
- 102100021013 Ubiquitin carboxyl-terminal hydrolase 7 Human genes 0.000 description 3
- 102100023485 Vitamin K epoxide reductase complex subunit 1 Human genes 0.000 description 3
- 101710104199 Vitamin K epoxide reductase complex subunit 1 Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000000820 nonprescription drug Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000004043 venous thromboembolism Diseases 0.000 description 3
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
- 101150028310 AKR1C3 gene Proteins 0.000 description 2
- 102100036817 Ankyrin-3 Human genes 0.000 description 2
- 101710191051 Ankyrin-3 Proteins 0.000 description 2
- 101150072227 CFHR5 gene Proteins 0.000 description 2
- 101150003340 CYP2C19 gene Proteins 0.000 description 2
- 101150109801 CYP2C8 gene Proteins 0.000 description 2
- 101150053096 CYP2C9 gene Proteins 0.000 description 2
- 101150068658 CYP4F2 gene Proteins 0.000 description 2
- 102220613084 Coagulation factor VII_R413Q_mutation Human genes 0.000 description 2
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 2
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 2
- 102220562796 Cytochrome P450 2C9_R150H_mutation Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010022894 Euchromatin Proteins 0.000 description 2
- 101150052158 F10 gene Proteins 0.000 description 2
- 101150105029 F11 gene Proteins 0.000 description 2
- 101150019878 F13a1 gene Proteins 0.000 description 2
- 101150036441 F5 gene Proteins 0.000 description 2
- 101150030532 F7 gene Proteins 0.000 description 2
- 101150083830 FGA gene Proteins 0.000 description 2
- 101150070116 FGG gene Proteins 0.000 description 2
- 108010074864 Factor XI Proteins 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 102000017911 HTR1A Human genes 0.000 description 2
- 108010034791 Heterochromatin Proteins 0.000 description 2
- 101001052043 Homo sapiens Fibrinogen gamma chain Proteins 0.000 description 2
- 101100521404 Homo sapiens PRSS53 gene Proteins 0.000 description 2
- 101000705917 Homo sapiens Serine protease 53 Proteins 0.000 description 2
- 101000663635 Homo sapiens Sphingosine kinase 1 Proteins 0.000 description 2
- 101000662997 Homo sapiens TRAF2 and NCK-interacting protein kinase Proteins 0.000 description 2
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 description 2
- 101000910758 Homo sapiens Voltage-dependent calcium channel gamma-2 subunit Proteins 0.000 description 2
- 101150003366 Hrg gene Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 101150056060 KNG1 gene Proteins 0.000 description 2
- 101150084690 LYZ gene Proteins 0.000 description 2
- 102100023170 Nuclear receptor subfamily 1 group D member 1 Human genes 0.000 description 2
- 101150110809 ORM1 gene Proteins 0.000 description 2
- 101150002928 PCGF3 gene Proteins 0.000 description 2
- 101150063839 PRSS53 gene Proteins 0.000 description 2
- 101150026061 STX4 gene Proteins 0.000 description 2
- 101100236128 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) LSM2 gene Proteins 0.000 description 2
- 101150116431 Slc44a2 gene Proteins 0.000 description 2
- 101150080374 Sphk1 gene Proteins 0.000 description 2
- 101150041750 Surf4 gene Proteins 0.000 description 2
- 102100037671 TRAF2 and NCK-interacting protein kinase Human genes 0.000 description 2
- 101150072974 TRPC4AP gene Proteins 0.000 description 2
- 101150025072 VKORC1 gene Proteins 0.000 description 2
- 102100024141 Voltage-dependent calcium channel gamma-2 subunit Human genes 0.000 description 2
- 101150099178 abo gene Proteins 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007451 chromatin immunoprecipitation sequencing Methods 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000013527 convolutional neural network Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000000632 euchromatin Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 210000004458 heterochromatin Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000012880 independent component analysis Methods 0.000 description 2
- 230000003426 interchromosomal effect Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000010238 partial least squares regression Methods 0.000 description 2
- 238000003068 pathway analysis Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000000955 prescription drug Substances 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 238000012628 principal component regression Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000013139 quantization Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000007637 random forest analysis Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 102200108072 rs1063856 Human genes 0.000 description 2
- 102220090107 rs17708472 Human genes 0.000 description 2
- 102200114854 rs5985 Human genes 0.000 description 2
- 102200042529 rs6050 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 101150032765 ARNTL gene Proteins 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 1
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 102000014814 CACNA1C Human genes 0.000 description 1
- 101150095166 CACNA1C gene Proteins 0.000 description 1
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 1
- 102000016897 CCCTC-Binding Factor Human genes 0.000 description 1
- 101150113634 CDKN1A gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 102100037529 Coagulation factor V Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102100030563 Coagulation factor XI Human genes 0.000 description 1
- 102100029057 Coagulation factor XIII A chain Human genes 0.000 description 1
- 108050006954 Coagulation factor XIII A chains Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000006912 Complement C4b-Binding Protein Human genes 0.000 description 1
- 108010047548 Complement C4b-Binding Protein Proteins 0.000 description 1
- 108010053085 Complement Factor H Proteins 0.000 description 1
- 102100035432 Complement factor H Human genes 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 102220563119 Cytochrome P450 2C9_I359L_mutation Human genes 0.000 description 1
- 102220562812 Cytochrome P450 2C9_R144C_mutation Human genes 0.000 description 1
- 108010064440 Cytochrome P450 Family 2 Proteins 0.000 description 1
- 102000015214 Cytochrome P450 Family 2 Human genes 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100029952 Double-strand-break repair protein rad21 homolog Human genes 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102100030651 Glutamate receptor 2 Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000584942 Homo sapiens Double-strand-break repair protein rad21 homolog Proteins 0.000 description 1
- 101000866287 Homo sapiens Excitatory amino acid transporter 2 Proteins 0.000 description 1
- 101001010449 Homo sapiens Glutamate receptor 2 Proteins 0.000 description 1
- 101000978926 Homo sapiens Nuclear receptor subfamily 1 group D member 1 Proteins 0.000 description 1
- 101100188855 Homo sapiens SCRIB gene Proteins 0.000 description 1
- 238000012351 Integrated analysis Methods 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 101710157490 Nuclear receptor subfamily 1 group D member 1 Proteins 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101150012695 Procr gene Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 102000012980 SLC1A2 Human genes 0.000 description 1
- 101710197594 Serine protease 53 Proteins 0.000 description 1
- 206010042220 Stress ulcer Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 101150045640 VWF gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102100032574 Voltage-dependent L-type calcium channel subunit alpha-1C Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229940124533 adjunct drug Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003467 cheek Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940105772 coagulation factor vii Drugs 0.000 description 1
- 108010045512 cohesins Proteins 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000013499 data model Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000573 exposure to toxins Toxicity 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 108010048325 fibrinopeptides gamma Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000006421 food insecurity Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 101150002245 grin2a gene Proteins 0.000 description 1
- 210000004326 gyrus cinguli Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 235000020938 metabolic status Nutrition 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 238000011457 non-pharmacological treatment Methods 0.000 description 1
- 210000002353 nuclear lamina Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 102220090106 rs8050894 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000133 toxic exposure Toxicity 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/08—Learning methods
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Data Mining & Analysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Theoretical Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Databases & Information Systems (AREA)
- Chemical & Material Sciences (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Artificial Intelligence (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Primary Health Care (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Computational Linguistics (AREA)
- General Physics & Mathematics (AREA)
- Mathematical Physics (AREA)
- Computing Systems (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (27)
- 統計モデリングおよび機械学習技術を使用して薬理学的表現型を特定するためのコンピュータ実施方法であって、前記方法が、前記方法を実行するようにプログラムされた1つ以上のプロセッサによって実行され、
1つ以上のプロセッサにおいて、複数の第1の患者の各々について、
前記第1の患者の生物学的特徴を示すパンオミックスデータ、
有害な文化的な外傷的事象、小児期の外傷的事象、急性の外傷的事象、もしくは慢性の外傷的事象、または有害な条件に起因する慢性ストレスに関連する危険因子を示すソシオミックスデータ、
経時的に収集された前記第1の患者の経験を示す環境データ、および
1つ以上の薬物に対する応答、前記第1の患者が物質乱用を経験しているかどうか、または前記第1の患者の1つ以上の慢性疾患、のうちの少なくとも1つを示す、表現型データ、を含む、訓練データのセットを取得することと、
前記訓練データのセットに基づいて、薬理学的表現型を判定するための統計モデルを前記1つ以上のプロセッサによって生成することと、
一定期間にわたって収集された第2の患者のパンオミックスデータ、ならびにソシオミックスデータおよび環境データのセットを、前記1つ以上のプロセッサにおいて受信することと、
前記1つ以上のプロセッサによって、前記統計モデルに前記第2の患者の前記パンオミックスデータ、ならびに前記ソシオミックスデータおよび環境データを適用して、前記第2の患者の1つ以上の薬理学的表現型を判定することと、
前記1つ以上のプロセッサによって、医療提供者に表示するための前記第2の患者の前記1つ以上の薬理学的表現型を提供することであって、前記医療提供者が、前記薬理学的表現型に従って、前記第2の患者に治療コースを推奨する、提供することと、を含む、方法。 - 前記ソシオミックスデータおよび環境データが、経時的に収集された前記第1の患者の経験を示し、少なくとも2つの時点から収集された前記第1の患者の病歴を示す臨床データ、前記第1の患者の人口統計学的データ、前記第1の患者の社会経済的データ、または前記第1の患者に処方された各薬物を示す多薬療法データ、のうちの少なくとも1つを含む、請求項1に記載の方法。
- 前記第2の患者の前記1つ以上の薬理学的表現型が、前記第2の患者による1つ以上の薬物に対する予測される応答、1つ以上の疾病のリスク、前記1つ以上の薬物に対する薬物有害事象もしくは薬物有害反応、または物質乱用の可能性、のうちの少なくとも1つを含む、請求項1または請求項2に記載の方法。
- 前記1つ以上の薬理学的表現型が、前記第2の患者による1つ以上の薬物に対する予測される応答を含み、
前記第2の患者について診断されたある種類の疾患の指標を、前記1つ以上のプロセッサにおいて受信することと、
前記1つ以上のプロセッサによって、前記統計モデルに前記第2の患者の前記パンオミックスデータならびに前記ソシオミックスデータおよび環境データを適用して、前記第2の患者について診断された前記種類の疾患を治療するための複数の薬物に対する前記第2の患者による前記予測される応答を判定することと、
前記1つ以上のプロセッサによって、前記複数の処方薬物の各々についての前記予測される応答に基づいて、前記第2の患者を治療するための前記複数の薬物のうちの1つを特定することと、
前記1つ以上のプロセッサによって、前記第2の患者について診断された前記種類の疾患に対する最適な治療コースを指示するために、前記医療提供者に前記特定された薬物の指標を提供することと、をさらに含む、請求項1〜3のいずれか一項に記載の方法。 - 前記予測される応答に基づいて、前記第2の患者を治療するための前記複数の薬物のうちの1つを特定することが、
前記複数の薬物の各々について、
前記1つ以上のプロセッサによって、前記第2の患者の前記パンオミックスデータならびに前記ソシオミックスデータおよび環境データに基づいて、前記第2の患者に対する前記薬物の有効性を判定することと、
前記1つ以上のプロセッサによって、前記第2の患者の前記パンオミックスデータならびに前記ソシオミックスデータおよび環境データに基づいて、前記第2の患者に対する1つ以上の予想される薬物有害反応を判定することと、
前記1つ以上のプロセッサによって、前記有効性および前記1つ以上の予想される薬物有害反応を組み合わせて、前記第2の患者に対する前記薬物の総合的価値を判定することと、
前記1つ以上のプロセッサによって、前記第2の患者に対する最も高い総合的価値を有する、前記複数の薬物のうちの前記薬物を特定することと、を含む、請求項4に記載の方法。 - 前記1つ以上の薬理学的表現型が、物質乱用の可能性を含み、
前記1つ以上のプロセッサによって、前記第2の患者の前記パンオミックスデータならびに前記ソシオミックスデータおよび環境データを前記統計モデルに適用して、前記第2の患者が閾値可能性を超える物質乱用の可能性を有すると判定することと、
前記1つ以上のプロセッサによって、早期介入のために前記医療提供者に表示するために、前記第2の患者が物質乱用問題に苦しむと予想される指標を提供することと、をさらに含む、請求項1〜5のいずれか一項に記載の方法。 - 医療提供者に表示するための前記第2の患者の前記1つ以上の薬理学的表現型を提供することが、
前記1つ以上のプロセッサによって、前記第2の患者による1つ以上の薬物の各々に対する予測される応答、1つ以上の疾病のリスク、または物質乱用の可能性、のうちの少なくとも1つを含む、前記第2の患者のリスク解析の表示を生成すること、を含む、請求項1〜6のいずれか一項に記載の方法。 - 閾値期間後に、前記1つ以上のプロセッサによって、1つ以上の薬物に対する応答、前記第2の患者が物質乱用を経験しているかどうか、または前記第2の患者の1つ以上の慢性疾患のうちの少なくとも1つを示す、前記第2の患者の表現型データを受信することと、
前記1つ以上のプロセッサによって、前記第2の患者の前記パンオミックスデータ、前記ソシオミックスデータおよび環境データ、ならびに前記表現型データを知識ベースに格納することと、
前記1つ以上のプロセッサによって、前記訓練データのセットを更新して、前記知識ベースからのデータを含めることと、をさらに含む、請求項1〜7のいずれか一項に記載の方法。 - パンオミックスデータが、ゲノムデータ、エピゲノムデータ、トランスクリプトームデータ、プロテオミクスデータ、クロモソミックスデータ、またはメタボロミクスデータのうちの少なくとも1つを含む、請求項1〜8のいずれか一項に記載の方法。
- 前記統計モデルが、1つ以上の機械学習技術を使用して生成される、請求項1〜9のいずれか一項に記載の方法。
- 薬理学的表現型を判定するための前記統計モデルを生成することが、
前記薬理学的表現型のセットと相関する複数の一塩基多型(SNP)を特定することと、
前記複数のSNPをSNPデータベースと比較して、前記複数のSNPにリンクされる追加のSNPを特定することであって、前記複数のSNPおよび追加のSNPが、許容候補バリアントのセットに含まれる、比較することと、
バイオインフォマティクス解析を実行して、調節機能、バリアント依存性、前記許容候補バリアントに対する標的遺伝子の関係の存在、または前記許容候補バリアントがマイナー対立遺伝子頻度を有する非同義コードバリアントであるかどうか、のうちの少なくとも1つに基づいて、前記許容候補バリアントのセットを中間候補バリアントのサブセットにフィルタリングすることと、
前記中間候補バリアントのサブセットを順位付けることと、
閾値順位を上回って順位付けられる前記サブセットのうちの中間候補バリアントを判定して、前記薬理学的表現型のセットとの因果関係があるSNP、前記SNPに関連付けられた遺伝子、または前記SNPに関連付けられた経路を特定することと、を含む、薬理学的表現型のセットに対応するパンオミックスデータを特定することを含む、請求項1〜10のいずれか一項に記載の方法。 - ワルファリン表現型のセットに対応するパンオミックスデータが特定され、前記ワルファリン表現型のセットとの因果関係がある前記特定された遺伝子または経路が、ワルファリン応答経路を含む、請求項11に記載の方法。
- 前記ワルファリン応答経路が、補体因子H関連5(CFHR5)遺伝子、フィブリノゲンα鎖(FGA)遺伝子、フラビン含有モノオキシゲナーゼ5(FMO5)遺伝子、ヒスチジンリッチ糖タンパク質(HRG)遺伝子、キニノーゲン1(KNG1)遺伝子、surfeit 4(SURF4)遺伝子、α1−3−N−アセチルガラクトサミニルトランスフェラーゼおよびα1−3−ガラクトシルトランスフェラーゼ(ABO)遺伝子、リゾチーム(LYZ)遺伝子、ポリコーム群リングフィンガー3(PCGF3)遺伝子、セリンプロテアーゼ8(PRSS8)遺伝子、一過性受容器電位カチオンチャネルサブファミリーCメンバー4関連タンパク質(TRPC4AP)遺伝子、溶質輸送体ファミリー44メンバー2(SLC44A2)遺伝子、スフィンゴシンキナーゼ1(SPHK1)遺伝子、またはユビキチン特異的ペプチダーゼ7(USP7)遺伝子、のうちの1つ以上を含む、請求項12に記載の方法。
- 前記ワルファリン表現型のセットが、凝固、出血、凝血、血栓症、または大量出血、のうちの1つ以上を含む、請求項12または請求項13に記載の方法。
- 前記第2の患者の前記パンオミックスデータならびに前記ソシオミックスデータおよび環境データを前記統計モデルに適用して、前記第2の患者の1つ以上の薬理学的表現型を判定することが、前記第2の患者の前記パンオミックスデータを前記ワルファリン応答経路内の遺伝子またはSNPと比較して、前記第2の患者の1つ以上のワルファリン表現型を判定することを含む、請求項12〜14のいずれか一項に記載の方法。
- 統計モデリングおよび機械学習技術を使用して薬理学的表現型を特定するためのコンピューティングデバイスであって、
通信網と、
1つ以上のプロセッサと、
非一時的コンピュータ可読メモリであって、前記1つ以上のプロセッサに結合されており、かつその上に命令を格納しており、前記命令が、前記1つ以上のプロセッサによって実行される場合、前記コンピューティングデバイスに、
複数の第1の患者の各々について、
前記第1の患者の生物学的特徴を示すパンオミックスデータ、
経時的に収集された前記第1の患者の経験を示すソシオミックスデータおよび環境データ、ならびに、
1つ以上の薬物に対する応答、前記第1の患者が物質乱用を経験しているかどうか、または前記第1の患者の1つ以上の慢性疾患、のうちの少なくとも1つを示す表現型データ、を含む、訓練データのセットを取得することと、
前記訓練データのセットに基づいて薬理学的表現型を判定するための統計モデルを生成することと、
一定期間にわたって収集された第2の患者のパンオミックスデータ、ならびにソシオミックスデータおよび環境データのセットを受信することと、
前記統計モデルに前記第2の患者の前記パンオミックスデータならびに前記ソシオミックスデータおよび環境データを適用して、前記第2の患者の1つ以上の薬理学的表現型を判定することと、
前記通信網を介して、医療提供者に表示するための前記第2の患者の前記1つ以上の薬理学的表現型を提供することと、を行わせ、前記医療提供者は、前記薬理学的表現型に従って前記第2の患者に治療コースを推奨する、非一時的コンピュータ可読メモリと、を備える、コンピューティングデバイス。 - 前記ソシオミックスデータおよび環境データが、経時的に収集された前記第1の患者の経験を示し、少なくとも2つの時点から収集された前記第1の患者の病歴を示す臨床データ、前記第1の患者の人口統計学的データ、前記第1の患者の社会経済的データ、または前記第1の患者に処方された各薬物を示す多薬療法データ、のうちの少なくとも1つを含む、請求項16に記載のコンピューティングデバイス。
- 前記第2の患者の前記1つ以上の薬理学的表現型が、前記第2の患者の1つ以上の薬物に対する予測される応答、1つ以上の疾病のリスク、前記1つ以上の薬物に対する薬物有害事象もしくは薬物有害反応、または物質乱用の可能性、のうちの少なくとも1つを含む、請求項16または請求項17に記載のコンピューティングデバイス。
- 前記1つ以上の薬理学的表現型が、前記第2の患者の1つ以上の薬物に対する予測される応答を含み、前記命令が、前記コンピューティングデバイスに、
前記第2の患者について診断された疾患の種類の指標を受信することと、
前記統計モデルに前記第2の患者の前記パンオミックスデータならびに前記ソシオミックスデータおよび環境データを適用して、前記第2の患者について診断された前記種類の疾患を治療するための複数の薬物に対する前記第2の患者の前記予測される応答を判定することと、
前記複数の処方薬物の各々についての前記予測される応答に基づいて、前記第2の患者を治療するための前記複数の薬物のうちの1つを特定することと、
前記第2の患者について診断された前記種類の疾患の最適な治療コースを指示するために、前記医療提供者に前記特定された薬物の指標を提供することと、をさらに行わせる、請求項16〜18のいずれか一項に記載のコンピューティングデバイス。 - 前記予測される応答に基づいて前記第2の患者を治療するための前記複数の薬物のうちの1つを特定するために、前記命令が、前記コンピューティングデバイスに、
前記複数の薬物の各々について、
前記第2の患者の前記パンオミックスデータならびに前記ソシオミックスデータおよび環境データに基づいて前記第2の患者に対する前記薬物の有効性を判定することと、
前記第2の患者について前記パンオミックスデータならびに前記ソシオミックスデータおよび環境データに基づいて、前記第2の患者に対する1つ以上の予想される薬物有害反応を判定することと、
前記有効性および前記1つ以上の予想される薬物有害反応を組み合わせて、前記第2の患者に対する前記薬物の総合的価値を判定することと、
前記複数の薬物から前記第2の患者に対する最も高い総合的価値を有する前記薬物を特定することと、を行わせる、請求項19に記載のコンピューティングデバイス。 - 前記1つ以上の薬理学的表現型が、ストレス関連障害、神経精神障害、不安障害、疼痛、物質乱用、心機能障害、または胃腸障害の可能性を含み、前記命令が、前記コンピューティングデバイスに、
前記統計モデルに前記第2の患者の前記パンオミックスデータならびに前記ソシオミックスデータおよび環境データを適用して、前記第2の患者が、閾値可能性を超える、ストレス関連障害、神経精神障害、不安障害、疼痛、物質乱用、心機能障害または胃腸障害の可能性を有すると判定することと、
早期介入のために医療提供者に表示する前記第2の患者がストレス関連障害、神経精神障害、不安障害、疼痛、物質乱用、心機能障害、または胃腸障害に苦しむと予想される指標を提供することと、を行わせる、請求項16〜20のいずれか一項に記載のコンピューティングデバイス。 - 医療提供者に表示する前記第2の患者の前記1つ以上の薬理学的表現型を提供するために、前記命令が、前記コンピューティングデバイスに、
前記第2の患者の1つ以上の薬物の各々に対する予測される応答、1つ以上の疾病のリスク、または物質乱用の可能性、のうちの少なくとも1つを含む、前記第2の患者のリスク解析の表示を生成することを行わせる、請求項16〜21のいずれか一項に記載のコンピューティングデバイス。 - 前記命令が、前記コンピューティングデバイスに、
閾値期間後に、1つ以上の薬物に対する応答、前記第2の患者が物質乱用を経験しているかどうか、または前記第2の患者の1つ以上の慢性疾患、のうちの少なくとも1つを示す、第2の患者の表現型データを受信することと、
前記第2の患者の前記パンオミックスデータ、前記ソシオミックスデータおよび環境データ、ならびに前記表現型データ、を知識ベースに格納することと、
前記訓練データのセットを更新して、前記知識ベースからのデータを含めることと、をさらに行わせる、請求項16〜22のいずれか一項に記載のコンピューティングデバイス。 - パンオミックスデータが、ゲノムデータ、エピゲノムデータ、トランスクリプトームデータ、プロテオミクスデータ、クロモソミックスデータ、またはメタボロミクスデータ、のうちの少なくとも1つを含む、請求項16〜23のいずれか一項に記載のコンピューティングデバイス。
- 前記統計モデルが、1つ以上の機械学習技術を使用して生成される、請求項16〜24のいずれか一項に記載のコンピューティングデバイス。
- 患者を治療するための方法であって、
患者の生体試料からパンオミックスデータを得ることと、
前記患者の前記パンオミックスデータをワルファリン応答経路内の1つ以上の遺伝子またはSNPと比較することと、
前記比較に基づいて、前記患者に投与するためのワルファリンの投与量を判定することと、
前記患者に前記判定された投与量のワルファリンを投与することと、を含む、方法。 - 前記ワルファリン応答経路が、補体因子H関連5(CFHR5)遺伝子、フィブリノゲンα鎖(FGA)遺伝子、フラビン含有モノオキシゲナーゼ5(FMO5)遺伝子、ヒスチジンリッチ糖タンパク質(HRG)遺伝子、キニノーゲン1(KNG1)遺伝子、surfeit 4(SURF4)遺伝子、α1−3−N−アセチルガラクトサミニルトランスフェラーゼおよびα1−3−ガラクトシルトランスフェラーゼ(ABO)遺伝子、リゾチーム(LYZ)遺伝子、ポリコーム群リングフィンガー3(PCGF3)遺伝子、セリンプロテアーゼ8(PRSS8)遺伝子、一過性受容器電位カチオンチャネルサブファミリーCメンバー4関連タンパク質(TRPC4AP)遺伝子、溶質輸送体ファミリー44メンバー2(SLC44A2)遺伝子、スフィンゴシンキナーゼ1(SPHK1)遺伝子、またはユビキチン特異的ペプチダーゼ7(USP7)遺伝子、のうちの1つ以上を含む、請求項26に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762505422P | 2017-05-12 | 2017-05-12 | |
US62/505,422 | 2017-05-12 | ||
US201862633355P | 2018-02-21 | 2018-02-21 | |
US62/633,355 | 2018-02-21 | ||
PCT/US2018/032179 WO2018209161A1 (en) | 2017-05-12 | 2018-05-11 | Individual and cohort pharmacological phenotype prediction platform |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020520510A true JP2020520510A (ja) | 2020-07-09 |
JP7390711B2 JP7390711B2 (ja) | 2023-12-04 |
Family
ID=62567748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019562325A Active JP7390711B2 (ja) | 2017-05-12 | 2018-05-11 | 個体およびコホートの薬理学的表現型予測プラットフォーム |
Country Status (7)
Country | Link |
---|---|
US (3) | US10249389B2 (ja) |
EP (1) | EP3622423A1 (ja) |
JP (1) | JP7390711B2 (ja) |
CN (1) | CN111742370A (ja) |
AU (1) | AU2018265421B2 (ja) |
CA (1) | CA3062858A1 (ja) |
WO (1) | WO2018209161A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023136354A1 (ja) * | 2022-01-17 | 2023-07-20 | 株式会社エイゾス | 統計データ取得装置、寄与度演算装置、治療行為探索装置、治療対象探索装置、統計データ取得プログラム、寄与度演算プログラム、治療行為探索プログラム、及び、治療対象探索プログラム |
Families Citing this family (147)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10437858B2 (en) * | 2011-11-23 | 2019-10-08 | 23Andme, Inc. | Database and data processing system for use with a network-based personal genetics services platform |
US8682906B1 (en) | 2013-01-23 | 2014-03-25 | Splunk Inc. | Real time display of data field values based on manual editing of regular expressions |
US9753909B2 (en) | 2012-09-07 | 2017-09-05 | Splunk, Inc. | Advanced field extractor with multiple positive examples |
US10394946B2 (en) | 2012-09-07 | 2019-08-27 | Splunk Inc. | Refining extraction rules based on selected text within events |
US20140208217A1 (en) | 2013-01-22 | 2014-07-24 | Splunk Inc. | Interface for managing splittable timestamps across event records |
US8751963B1 (en) | 2013-01-23 | 2014-06-10 | Splunk Inc. | Real time indication of previously extracted data fields for regular expressions |
US9152929B2 (en) | 2013-01-23 | 2015-10-06 | Splunk Inc. | Real time display of statistics and values for selected regular expressions |
US20210005324A1 (en) * | 2018-08-08 | 2021-01-07 | Hc1.Com Inc. | Methods and systems for a health monitoring command center and workforce advisor |
US11990246B2 (en) * | 2018-06-29 | 2024-05-21 | Health Solutions Research, Inc. | Identifying patients undergoing treatment with a drug who may be misidentified as being at risk for abusing the treatment drug |
US11688521B2 (en) * | 2018-06-29 | 2023-06-27 | Health Solutions Research, Inc. | Risk stratification for adverse health outcomes |
CN111742370A (zh) | 2017-05-12 | 2020-10-02 | 密歇根大学董事会 | 个体和队列药理学表型预测平台 |
US10522252B2 (en) | 2017-06-16 | 2019-12-31 | Carefusion 303, Inc. | Opioid management system |
IL299565B1 (en) | 2017-10-16 | 2024-03-01 | Illumina Inc | Classifies pathogenic variants using a recurrent neural network |
US11861491B2 (en) | 2017-10-16 | 2024-01-02 | Illumina, Inc. | Deep learning-based pathogenicity classifier for promoter single nucleotide variants (pSNVs) |
US10540591B2 (en) * | 2017-10-16 | 2020-01-21 | Illumina, Inc. | Deep learning-based techniques for pre-training deep convolutional neural networks |
KR102003607B1 (ko) * | 2017-11-02 | 2019-07-24 | 이화여자대학교 산학협력단 | 외상 사건에 의한 행동 문제 예측 방법 및 행동 문제 예측 장치 |
US20190156923A1 (en) | 2017-11-17 | 2019-05-23 | LunaPBC | Personal, omic, and phenotype data community aggregation platform |
US11227692B2 (en) * | 2017-12-28 | 2022-01-18 | International Business Machines Corporation | Neuron model simulation |
US10950354B1 (en) * | 2018-03-02 | 2021-03-16 | Allscripts Software, Llc | Computing system for pharmacogenomics |
EP3788634A1 (en) | 2018-05-04 | 2021-03-10 | CareFusion 303, Inc. | Peer community based anomalous behavior detection |
CA3109275A1 (en) * | 2018-08-17 | 2020-02-20 | Ancestry.Com Dna, Llc | Prediction of phenotypes using recommender systems |
US10896742B2 (en) | 2018-10-31 | 2021-01-19 | Ancestry.Com Dna, Llc | Estimation of phenotypes using DNA, pedigree, and historical data |
CN109585020A (zh) * | 2018-11-27 | 2019-04-05 | 华侨大学 | 一种运用卷积神经网络对疾病风险预测的模型 |
JP7316358B2 (ja) * | 2018-11-29 | 2023-07-27 | ジャニュアリー, インコーポレイテッド | 生物物理学的モデル化および応答予測のためのシステム、方法、およびデバイス |
US11664108B2 (en) | 2018-11-29 | 2023-05-30 | January, Inc. | Systems, methods, and devices for biophysical modeling and response prediction |
CN109636026B (zh) * | 2018-12-07 | 2023-02-28 | 东华大学 | 一种基于深度学习模型的晶圆良率预测方法 |
CN109411019B (zh) * | 2018-12-12 | 2020-05-05 | 中国人民解放军军事科学院军事医学研究院 | 一种药物预测方法、装置、服务器及存储介质 |
US11676719B2 (en) * | 2018-12-20 | 2023-06-13 | Oregon Health & Science University | Subtyping heterogeneous disorders using functional random forest models |
US11620544B2 (en) * | 2018-12-21 | 2023-04-04 | TeselaGen Biotechnology Inc. | Method, apparatus, and computer-readable medium for efficiently optimizing a phenotype with a specialized prediction model |
EP3903316A1 (en) | 2018-12-28 | 2021-11-03 | LunaPBC | Community data aggregation, completion, correction, and use |
US11804295B2 (en) * | 2019-01-07 | 2023-10-31 | Carefusion 303, Inc. | Machine learning based safety controller |
US11984212B2 (en) | 2019-01-10 | 2024-05-14 | Carefusion 303, Inc. | System for monitoring dose pattern and patient response |
US11721441B2 (en) * | 2019-01-15 | 2023-08-08 | Merative Us L.P. | Determining drug effectiveness ranking for a patient using machine learning |
EP3912166A1 (en) | 2019-01-18 | 2021-11-24 | CareFusion 303, Inc. | Medication tracking system |
EP3915120A1 (en) | 2019-01-23 | 2021-12-01 | The Regents of the University of Michigan | Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors |
US20200243165A1 (en) * | 2019-01-28 | 2020-07-30 | International Business Machines Corporation | Prediction model for determining whether feature vector of data in each of multiple input sequences should be added to that of the other data in the sequence |
US11302443B2 (en) * | 2019-02-25 | 2022-04-12 | International Business Machines Corporation | Systems and methods for alerting on ambiguous advice of medical decision support systems |
EP3931844A1 (en) * | 2019-02-26 | 2022-01-05 | Flatiron Health, Inc. | Prognostic score based on health information |
US11541274B2 (en) | 2019-03-11 | 2023-01-03 | Rom Technologies, Inc. | System, method and apparatus for electrically actuated pedal for an exercise or rehabilitation machine |
US11904202B2 (en) | 2019-03-11 | 2024-02-20 | Rom Technolgies, Inc. | Monitoring joint extension and flexion using a sensor device securable to an upper and lower limb |
US11185735B2 (en) | 2019-03-11 | 2021-11-30 | Rom Technologies, Inc. | System, method and apparatus for adjustable pedal crank |
US11210554B2 (en) | 2019-03-21 | 2021-12-28 | Illumina, Inc. | Artificial intelligence-based generation of sequencing metadata |
US11347965B2 (en) | 2019-03-21 | 2022-05-31 | Illumina, Inc. | Training data generation for artificial intelligence-based sequencing |
US11904207B2 (en) | 2019-05-10 | 2024-02-20 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to present a user interface representing a user's progress in various domains |
US11957960B2 (en) | 2019-05-10 | 2024-04-16 | Rehab2Fit Technologies Inc. | Method and system for using artificial intelligence to adjust pedal resistance |
US11433276B2 (en) | 2019-05-10 | 2022-09-06 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to independently adjust resistance of pedals based on leg strength |
US11801423B2 (en) | 2019-05-10 | 2023-10-31 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to interact with a user of an exercise device during an exercise session |
US11593649B2 (en) | 2019-05-16 | 2023-02-28 | Illumina, Inc. | Base calling using convolutions |
WO2020236481A1 (en) * | 2019-05-17 | 2020-11-26 | Kutzko John D | Computer-implemented system and methods for predicting the health and therapeutic behavior of individuals using artificial intelligence, smart contracts and blockchain |
EP3976829A4 (en) * | 2019-05-30 | 2023-07-12 | PolygenRx Pty Ltd | METHOD OF TREATMENT OR PROPHYLAXIS |
US20200381095A1 (en) * | 2019-05-31 | 2020-12-03 | International Business Machines Corporation | Personalized medication non-adherence evaluation |
US20200381083A1 (en) * | 2019-05-31 | 2020-12-03 | 410 Ai, Llc | Estimating predisposition for disease based on classification of artificial image objects created from omics data |
CN110298564A (zh) * | 2019-06-17 | 2019-10-01 | 迪普佰奥生物科技(上海)有限公司 | 基于人工智能的生物医药产品评价方法、装置、介质、终端 |
US10515715B1 (en) | 2019-06-25 | 2019-12-24 | Colgate-Palmolive Company | Systems and methods for evaluating compositions |
US20200411185A1 (en) * | 2019-06-27 | 2020-12-31 | Mahana Therapeutics, Inc. | Adaptive interventions for gastrointestinal health conditions |
US11676727B2 (en) | 2019-08-14 | 2023-06-13 | Optum Technology, Inc. | Cohort-based predictive data analysis |
WO2021041663A1 (en) * | 2019-08-27 | 2021-03-04 | Prescient Medicine Holdings, Inc. | Methods and systems for evaluation of risk of substance use disorders |
US11701548B2 (en) | 2019-10-07 | 2023-07-18 | Rom Technologies, Inc. | Computer-implemented questionnaire for orthopedic treatment |
US11071597B2 (en) | 2019-10-03 | 2021-07-27 | Rom Technologies, Inc. | Telemedicine for orthopedic treatment |
WO2021055856A1 (en) * | 2019-09-18 | 2021-03-25 | Millennium Health, LLC | Tool for predicting health and drug abuse crisis |
US20210082575A1 (en) * | 2019-09-18 | 2021-03-18 | Cerner Innovation, Inc. | Computerized decision support tool for post-acute care patients |
USD928635S1 (en) | 2019-09-18 | 2021-08-24 | Rom Technologies, Inc. | Goniometer |
US20210090745A1 (en) * | 2019-09-20 | 2021-03-25 | Iqvia Inc. | Unbiased etl system for timed medical event prediction |
EP3799068A1 (en) * | 2019-09-24 | 2021-03-31 | Siemens Healthcare GmbH | System and method for infectious disease notification |
US20210134425A1 (en) | 2019-10-03 | 2021-05-06 | Rom Technologies, Inc. | System and method for using artificial intelligence in telemedicine-enabled hardware to optimize rehabilitative routines capable of enabling remote rehabilitative compliance |
US11923065B2 (en) | 2019-10-03 | 2024-03-05 | Rom Technologies, Inc. | Systems and methods for using artificial intelligence and machine learning to detect abnormal heart rhythms of a user performing a treatment plan with an electromechanical machine |
US11325005B2 (en) | 2019-10-03 | 2022-05-10 | Rom Technologies, Inc. | Systems and methods for using machine learning to control an electromechanical device used for prehabilitation, rehabilitation, and/or exercise |
US11887717B2 (en) | 2019-10-03 | 2024-01-30 | Rom Technologies, Inc. | System and method for using AI, machine learning and telemedicine to perform pulmonary rehabilitation via an electromechanical machine |
US11075000B2 (en) | 2019-10-03 | 2021-07-27 | Rom Technologies, Inc. | Method and system for using virtual avatars associated with medical professionals during exercise sessions |
US20210134412A1 (en) | 2019-10-03 | 2021-05-06 | Rom Technologies, Inc. | System and method for processing medical claims using biometric signatures |
US11139060B2 (en) | 2019-10-03 | 2021-10-05 | Rom Technologies, Inc. | Method and system for creating an immersive enhanced reality-driven exercise experience for a user |
US11955222B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria |
US20210128080A1 (en) | 2019-10-03 | 2021-05-06 | Rom Technologies, Inc. | Augmented reality placement of goniometer or other sensors |
US11069436B2 (en) | 2019-10-03 | 2021-07-20 | Rom Technologies, Inc. | System and method for use of telemedicine-enabled rehabilitative hardware and for encouraging rehabilitative compliance through patient-based virtual shared sessions with patient-enabled mutual encouragement across simulated social networks |
US11282604B2 (en) | 2019-10-03 | 2022-03-22 | Rom Technologies, Inc. | Method and system for use of telemedicine-enabled rehabilitative equipment for prediction of secondary disease |
US11265234B2 (en) | 2019-10-03 | 2022-03-01 | Rom Technologies, Inc. | System and method for transmitting data and ordering asynchronous data |
US11955223B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning to provide an enhanced user interface presenting data pertaining to cardiac health, bariatric health, pulmonary health, and/or cardio-oncologic health for the purpose of performing preventative actions |
US11282599B2 (en) | 2019-10-03 | 2022-03-22 | Rom Technologies, Inc. | System and method for use of telemedicine-enabled rehabilitative hardware and for encouragement of rehabilitative compliance through patient-based virtual shared sessions |
US11915815B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning and generic risk factors to improve cardiovascular health such that the need for additional cardiac interventions is mitigated |
US11337648B2 (en) * | 2020-05-18 | 2022-05-24 | Rom Technologies, Inc. | Method and system for using artificial intelligence to assign patients to cohorts and dynamically controlling a treatment apparatus based on the assignment during an adaptive telemedical session |
US20210134432A1 (en) | 2019-10-03 | 2021-05-06 | Rom Technologies, Inc. | Method and system for implementing dynamic treatment environments based on patient information |
US11915816B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | Systems and methods of using artificial intelligence and machine learning in a telemedical environment to predict user disease states |
US11270795B2 (en) | 2019-10-03 | 2022-03-08 | Rom Technologies, Inc. | Method and system for enabling physician-smart virtual conference rooms for use in a telehealth context |
US20210127974A1 (en) | 2019-10-03 | 2021-05-06 | Rom Technologies, Inc. | Remote examination through augmented reality |
US11955220B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML and telemedicine for invasive surgical treatment to determine a cardiac treatment plan that uses an electromechanical machine |
US11515028B2 (en) | 2019-10-03 | 2022-11-29 | Rom Technologies, Inc. | Method and system for using artificial intelligence and machine learning to create optimal treatment plans based on monetary value amount generated and/or patient outcome |
US11978559B2 (en) | 2019-10-03 | 2024-05-07 | Rom Technologies, Inc. | Systems and methods for remotely-enabled identification of a user infection |
US11515021B2 (en) | 2019-10-03 | 2022-11-29 | Rom Technologies, Inc. | Method and system to analytically optimize telehealth practice-based billing processes and revenue while enabling regulatory compliance |
US11756666B2 (en) | 2019-10-03 | 2023-09-12 | Rom Technologies, Inc. | Systems and methods to enable communication detection between devices and performance of a preventative action |
US20210142893A1 (en) | 2019-10-03 | 2021-05-13 | Rom Technologies, Inc. | System and method for processing medical claims |
US11087865B2 (en) | 2019-10-03 | 2021-08-10 | Rom Technologies, Inc. | System and method for use of treatment device to reduce pain medication dependency |
US11830601B2 (en) | 2019-10-03 | 2023-11-28 | Rom Technologies, Inc. | System and method for facilitating cardiac rehabilitation among eligible users |
US11961603B2 (en) | 2019-10-03 | 2024-04-16 | Rom Technologies, Inc. | System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine |
US11282608B2 (en) | 2019-10-03 | 2022-03-22 | Rom Technologies, Inc. | Method and system for using artificial intelligence and machine learning to provide recommendations to a healthcare provider in or near real-time during a telemedicine session |
US11955221B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis |
US20210134458A1 (en) | 2019-10-03 | 2021-05-06 | Rom Technologies, Inc. | System and method to enable remote adjustment of a device during a telemedicine session |
US11101028B2 (en) | 2019-10-03 | 2021-08-24 | Rom Technologies, Inc. | Method and system using artificial intelligence to monitor user characteristics during a telemedicine session |
US11317975B2 (en) | 2019-10-03 | 2022-05-03 | Rom Technologies, Inc. | Method and system for treating patients via telemedicine using sensor data from rehabilitation or exercise equipment |
US11826613B2 (en) | 2019-10-21 | 2023-11-28 | Rom Technologies, Inc. | Persuasive motivation for orthopedic treatment |
US11715565B2 (en) * | 2019-11-08 | 2023-08-01 | Tempus Labs, Inc. | Evaluating effect of event on condition using propensity scoring |
US11645565B2 (en) | 2019-11-12 | 2023-05-09 | Optum Services (Ireland) Limited | Predictive data analysis with cross-temporal probabilistic updates |
EP3822974A1 (en) * | 2019-11-15 | 2021-05-19 | Stalicla S.A. | Computational platform to identify therapeutic treatments for neurodevelopmental conditions |
US10734105B1 (en) * | 2019-11-30 | 2020-08-04 | Kpn Innovations, Llc | Methods and systems for informed selection of prescriptive therapies |
USD907143S1 (en) | 2019-12-17 | 2021-01-05 | Rom Technologies, Inc. | Rehabilitation device |
US11684299B2 (en) | 2019-12-17 | 2023-06-27 | Mahana Therapeutics, Inc. | Method and system for remotely monitoring the psychological state of an application user using machine learning-based models |
US11967401B2 (en) * | 2019-12-26 | 2024-04-23 | Kpn Innovations, Llc | Methods and systems for physiologically informed network searching |
US11694810B2 (en) * | 2020-02-12 | 2023-07-04 | MDI Health Technologies Ltd | Systems and methods for computing risk of predicted medical outcomes in patients treated with multiple medications |
EP4107735A2 (en) | 2020-02-20 | 2022-12-28 | Illumina, Inc. | Artificial intelligence-based many-to-many base calling |
AU2021226736A1 (en) | 2020-02-25 | 2022-09-01 | Becton, Dickinson And Company | Systems and methods for dynamic surveillance of medication and antimicrobial resistance trends |
US11763946B2 (en) | 2020-02-27 | 2023-09-19 | Optum, Inc. | Graph-based predictive inference |
US11107591B1 (en) | 2020-04-23 | 2021-08-31 | Rom Technologies, Inc. | Method and system for describing and recommending optimal treatment plans in adaptive telemedical or other contexts |
JP6989860B2 (ja) * | 2020-05-02 | 2022-01-12 | Arithmer株式会社 | 画像検査装置、画像検査方法及びプログラム |
US11461216B1 (en) | 2020-05-18 | 2022-10-04 | Vignet Incorporated | Monitoring and improving data collection using digital health technology |
US11605038B1 (en) | 2020-05-18 | 2023-03-14 | Vignet Incorporated | Selecting digital health technology to achieve data collection compliance in clinical trials |
US20210375455A1 (en) * | 2020-05-27 | 2021-12-02 | MediSync, Inc. | Artificial intelligence systems that incorporate expert knowledge related to heart failure |
US11610663B2 (en) | 2020-05-29 | 2023-03-21 | Mahana Therapeutics, Inc. | Method and system for remotely identifying and monitoring anomalies in the physical and/or psychological state of an application user using average physical activity data associated with a set of people other than the user |
US11967432B2 (en) | 2020-05-29 | 2024-04-23 | Mahana Therapeutics, Inc. | Method and system for remotely monitoring the physical and psychological state of an application user using altitude and/or motion data and one or more machine learning models |
CN111627515B (zh) * | 2020-05-29 | 2023-07-18 | 上海商汤智能科技有限公司 | 药物推荐方法、装置、电子设备及介质 |
CN111753543B (zh) * | 2020-06-24 | 2024-03-12 | 北京百度网讯科技有限公司 | 药物推荐方法、装置、电子设备及存储介质 |
WO2022006676A1 (en) * | 2020-07-09 | 2022-01-13 | Mcmaster University | Machine learning prediction of biological effect in multicellular animals from microorganism transcriptional fingerprint patterns in non-inhibitory chemical challenge |
CN111816252B (zh) * | 2020-07-21 | 2021-08-31 | 腾讯科技(深圳)有限公司 | 一种药物筛选方法、装置及电子设备 |
US11335443B1 (en) * | 2020-09-07 | 2022-05-17 | OpenNano Pte. Ltd. | Phenotypic patient data derivation from economic data |
CN111916210A (zh) * | 2020-09-30 | 2020-11-10 | 平安科技(深圳)有限公司 | 辅助诊断方法、装置、服务器及存储介质 |
KR20230107219A (ko) * | 2020-10-06 | 2023-07-14 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 엑스포솜 임상 적용을 위한 시스템 및 방법 |
CN112017732B (zh) * | 2020-10-23 | 2021-02-05 | 平安科技(深圳)有限公司 | 一种终端设备、装置、疾病分类方法及可读存储介质 |
CN112435757A (zh) * | 2020-10-27 | 2021-03-02 | 深圳市利来山科技有限公司 | 一种急性肝炎的预测装置及系统 |
WO2022094088A1 (en) * | 2020-10-28 | 2022-05-05 | Tabula Rasa Healthcare, Inc. | System and method of processing pharmaceutical substance data |
CN112309567B (zh) * | 2020-11-06 | 2021-06-01 | 浙江大学 | 临床药师工作站智能化管理系统及方法 |
CN112527020B (zh) * | 2020-11-30 | 2023-07-25 | 汕头大学 | 一种基于群体机器人的目标围捕控制方法及系统 |
US11232870B1 (en) * | 2020-12-09 | 2022-01-25 | Neura Labs Ltd. | Communicable disease prediction and control based on behavioral indicators derived using machine learning |
CN112669991A (zh) * | 2020-12-28 | 2021-04-16 | 山东健康医疗大数据有限公司 | 一种药品不良反应信号检出方法 |
CN112837752B (zh) * | 2021-02-02 | 2022-03-04 | 中南大学 | 一种基于多网络融合和多层网络扩散的抑郁障碍基因特征挖掘方法 |
US11132598B1 (en) * | 2021-02-23 | 2021-09-28 | Neuraville, Llc | System and method for humanoid robot control and cognitive self-improvement without programming |
CN113077849B (zh) * | 2021-03-16 | 2023-03-31 | 华南农业大学 | 一种大肠杆菌β-内酰胺类获得性耐药表型预测复合方法 |
CN113241115A (zh) * | 2021-03-26 | 2021-08-10 | 广东工业大学 | 一种基于深度矩阵分解的环状rna疾病关联预测方法 |
US20220336054A1 (en) | 2021-04-15 | 2022-10-20 | Illumina, Inc. | Deep Convolutional Neural Networks to Predict Variant Pathogenicity using Three-Dimensional (3D) Protein Structures |
AU2022300269A1 (en) * | 2021-06-22 | 2024-01-25 | Scipher Medicine Corporation | Methods and systems for therapy monitoring and trial design |
WO2023083485A1 (en) | 2021-11-15 | 2023-05-19 | NEC Laboratories Europe GmbH | A method for operating a patient survival assessment system and a corresponding data processing system |
US11901083B1 (en) | 2021-11-30 | 2024-02-13 | Vignet Incorporated | Using genetic and phenotypic data sets for drug discovery clinical trials |
US11705230B1 (en) | 2021-11-30 | 2023-07-18 | Vignet Incorporated | Assessing health risks using genetic, epigenetic, and phenotypic data sources |
WO2023114031A1 (en) * | 2021-12-16 | 2023-06-22 | Plan Heal Health Companies, Inc. | Machine learning methods and systems for phenotype classifications |
CN117033993A (zh) * | 2022-04-29 | 2023-11-10 | 华东交通大学 | 一种基于最小角排序选择的优选训练集的方法 |
US20230368879A1 (en) * | 2022-05-13 | 2023-11-16 | Cipherome, Inc. | Health and medical history visualization and prediction using machine-learning and artificial intelligence models |
CN115312182B (zh) * | 2022-07-26 | 2023-06-27 | 哈尔滨工业大学 | 一种预测疫苗接种后不良反应转为严重不良反应风险的模型 |
CN115148375B (zh) * | 2022-08-31 | 2022-11-15 | 之江实验室 | 一种高通量真实世界药物有效性与安全性评价方法及系统 |
CN115662656B (zh) * | 2022-11-04 | 2023-11-07 | 上海康黎医学检验所有限公司 | 一种药物副作用的评价方法、系统和电子设备 |
CN116779186B (zh) * | 2023-08-23 | 2023-12-12 | 寿光市人民医院 | 一种用于心律失常患者的环磷腺苷用药数据信息处理系统 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020077756A1 (en) * | 1999-11-29 | 2002-06-20 | Scott Arouh | Neural-network-based identification, and application, of genomic information practically relevant to diverse biological and sociological problems, including drug dosage estimation |
JP2008523844A (ja) * | 2004-12-21 | 2008-07-10 | アカデミア シニカ | ワルファリン感受性を予測するvkorc1の遺伝的変異 |
JP2017502365A (ja) * | 2013-10-08 | 2017-01-19 | コタ インコーポレイテッド | 臨床転帰トラッキング及び分析 |
JP2017509622A (ja) * | 2014-03-31 | 2017-04-06 | 第一三共株式会社 | 抗凝固薬として使用されるビタミンK拮抗薬に感受性を有する患者における、出血事象及び関連障害を治療及び予防するための第Xa因子阻害薬の使用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040091933A1 (en) * | 2001-07-02 | 2004-05-13 | Roland Stoughton | Methods for genetic interpretation and prediction of phenotype |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
US20050196771A1 (en) * | 2002-04-11 | 2005-09-08 | Matt Neville | Characterization of CYP 2D6 genotypes |
JP5348840B2 (ja) | 2003-02-20 | 2013-11-20 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 薬物を選択する方法 |
US20060034508A1 (en) * | 2004-06-07 | 2006-02-16 | Zhou Xiang S | Computer system and method for medical assistance with imaging and genetics information fusion |
CA2623938A1 (en) * | 2005-09-30 | 2007-04-05 | Perlegen Sciences, Inc. | Methods and compositions for screening and treatment of disorders of blood glucose regulation |
US7695911B2 (en) * | 2005-10-26 | 2010-04-13 | Celera Corporation | Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof |
DK2508621T3 (en) * | 2005-11-29 | 2015-01-12 | Childrens Hosp Medical Center | Optimization and individualization of drug selection and dosage |
JP2012507297A (ja) * | 2008-10-29 | 2012-03-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Erbb4遺伝子の多型に基づく精神病及び統合失調症の治療法 |
EP2742154A4 (en) | 2011-08-08 | 2015-08-12 | Caris Life Sciences Switzerland Holdings Gmbh | BIOMARKER COMPOSITIONS AND METHODS |
CA2866017C (en) * | 2012-03-09 | 2019-09-10 | Bombardier Inc. | Mechanism and method for arming/disarming the actuation of an emergency slide |
US20140038836A1 (en) | 2012-05-29 | 2014-02-06 | Assurerx Health, Inc. | Novel Pharmacogene Single Nucleotide Polymorphisms and Methods of Detecting Same |
US20140046696A1 (en) | 2012-08-10 | 2014-02-13 | Assurerx Health, Inc. | Systems and Methods for Pharmacogenomic Decision Support in Psychiatry |
US9938576B1 (en) * | 2012-09-21 | 2018-04-10 | Ohio State Innovation Foundation | Materials and methods for determining metabolizer status in humans |
US20140222349A1 (en) | 2013-01-16 | 2014-08-07 | Assurerx Health, Inc. | System and Methods for Pharmacogenomic Classification |
DK3005199T3 (da) * | 2013-05-28 | 2019-10-14 | Five3 Genomics Llc | Paradigme-medikament respons netværk |
JP6596424B2 (ja) * | 2013-12-12 | 2019-10-23 | アビ−バイオティクス エス.エー. | 薬剤の使用に関する個人別推奨案をコンピュータの補助のもとでウエブ・ベースで提供する方法とシステムとコンピュータで読み取り可能な記憶媒体 |
US20150347699A1 (en) * | 2014-06-03 | 2015-12-03 | Collabrx, Inc. | Actionability framework for genomic biomarker |
US20190015415A1 (en) * | 2015-09-30 | 2019-01-17 | Indivior Uk Limited | Methods for treating schizophrenia |
CN111742370A (zh) * | 2017-05-12 | 2020-10-02 | 密歇根大学董事会 | 个体和队列药理学表型预测平台 |
WO2019195638A1 (en) * | 2018-04-04 | 2019-10-10 | Human Longevity, Inc. | Systems and methods for measuring obesity using metabolome analysis |
-
2018
- 2018-05-11 CN CN201880046200.7A patent/CN111742370A/zh active Pending
- 2018-05-11 CA CA3062858A patent/CA3062858A1/en active Pending
- 2018-05-11 AU AU2018265421A patent/AU2018265421B2/en active Active
- 2018-05-11 JP JP2019562325A patent/JP7390711B2/ja active Active
- 2018-05-11 US US15/977,347 patent/US10249389B2/en active Active
- 2018-05-11 EP EP18730490.2A patent/EP3622423A1/en active Pending
- 2018-05-11 WO PCT/US2018/032179 patent/WO2018209161A1/en active Search and Examination
-
2019
- 2019-02-05 US US16/267,546 patent/US10553318B2/en active Active
- 2019-12-23 US US16/725,279 patent/US10867702B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020077756A1 (en) * | 1999-11-29 | 2002-06-20 | Scott Arouh | Neural-network-based identification, and application, of genomic information practically relevant to diverse biological and sociological problems, including drug dosage estimation |
JP2008523844A (ja) * | 2004-12-21 | 2008-07-10 | アカデミア シニカ | ワルファリン感受性を予測するvkorc1の遺伝的変異 |
JP2017502365A (ja) * | 2013-10-08 | 2017-01-19 | コタ インコーポレイテッド | 臨床転帰トラッキング及び分析 |
JP2017509622A (ja) * | 2014-03-31 | 2017-04-06 | 第一三共株式会社 | 抗凝固薬として使用されるビタミンK拮抗薬に感受性を有する患者における、出血事象及び関連障害を治療及び予防するための第Xa因子阻害薬の使用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023136354A1 (ja) * | 2022-01-17 | 2023-07-20 | 株式会社エイゾス | 統計データ取得装置、寄与度演算装置、治療行為探索装置、治療対象探索装置、統計データ取得プログラム、寄与度演算プログラム、治療行為探索プログラム、及び、治療対象探索プログラム |
Also Published As
Publication number | Publication date |
---|---|
US10249389B2 (en) | 2019-04-02 |
AU2018265421A1 (en) | 2019-12-12 |
CN111742370A (zh) | 2020-10-02 |
AU2018265421B2 (en) | 2024-03-07 |
CA3062858A1 (en) | 2018-11-15 |
WO2018209161A1 (en) | 2018-11-15 |
US10553318B2 (en) | 2020-02-04 |
JP7390711B2 (ja) | 2023-12-04 |
US20180330824A1 (en) | 2018-11-15 |
EP3622423A1 (en) | 2020-03-18 |
US10867702B2 (en) | 2020-12-15 |
US20190172584A1 (en) | 2019-06-06 |
US20200135337A1 (en) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10867702B2 (en) | Individual and cohort pharmacological phenotype prediction platform | |
Spooner et al. | A comparison of machine learning methods for survival analysis of high-dimensional clinical data for dementia prediction | |
Bush et al. | Unravelling the human genome–phenome relationship using phenome-wide association studies | |
Beesley et al. | The emerging landscape of health research based on biobanks linked to electronic health records: Existing resources, statistical challenges, and potential opportunities | |
Wanichthanarak et al. | Genomic, proteomic, and metabolomic data integration strategies | |
Hossain et al. | Use of electronic health data for disease prediction: A comprehensive literature review | |
Agerbo et al. | Polygenic risk score, parental socioeconomic status, family history of psychiatric disorders, and the risk for schizophrenia: a Danish population-based study and meta-analysis | |
US20180301205A1 (en) | Efficient clinical trial matching | |
Sarkar et al. | Translational bioinformatics: linking knowledge across biological and clinical realms | |
Jia et al. | RDAD: a machine learning system to support phenotype-based rare disease diagnosis | |
US11798651B2 (en) | Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis | |
CN113597645A (zh) | 用于重建药物应答和疾病网络的方法和系统以及其用途 | |
Fathallah-Shaykh | Microarrays: applications and pitfalls | |
Walters Jr et al. | Automated phenotyping tool for identifying developmental language disorder cases in health systems data (APT-DLD): A new research algorithm for deployment in large-scale electronic health record systems | |
Sethi et al. | Translational bioinformatics and healthcare informatics: computational and ethical challenges | |
Highnam et al. | Personal genomes and precision medicine | |
Mullany et al. | Effectiveness and usability of bioinformatics tools to analyze pathways associated with miRNA expression | |
Tenenbaum et al. | Translational bioinformatics | |
Schork et al. | Report: NIA workshop on translating genetic variants associated with longevity into drug targets | |
Hu et al. | Omnibus proteome-wide association study (PWAS-O) identified 43 risk genes for Alzheimer’s disease dementia | |
Panagiota | Business analytics in healthcare operations and the use of mobile applications for decision making by health professionals | |
Estapé et al. | Data mining to transform clinical and translational research findings into precision health | |
Bano et al. | Computational Intelligence Methods for Biomarkers Discovery in Autoimmune Diseases: Case Studies | |
Manzini et al. | Current and emerging capabilities of AI-powered genomics, and associated ethical, legal and political debates | |
Sarata | Genetic Testing: Background and Policy Issues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210326 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220428 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220826 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221101 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230301 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230302 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20230324 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230426 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230428 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230526 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231114 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7390711 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |